Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- The Rosen Law Firm PAROSEN, A LONGSTANDING LAW FIRM, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - UNCYWHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) between December 29, 2025 and June 29, 2026, both dates inclusive (the "Class Period"), of the important November 2, 2026 lead plaintiff deadline.SO WHAT: If you purchased Unicycive securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs...
- AnnJi Pharmaceutical überführt AJ201 in die zulassungsrelevante Phase-3-Studie „ROMA-KD" zur Behandlung der spinalen und bulbären Muskelatrophie (SBMA)Die weltweit einzige bekannte Prüftherapie in der klinischen Phase 3 zur Behandlung von SBMA AJ201 (Rosolutamid) ist ein in der Erprobung befindliches, oral verabreichtes niedermolekulares Präparat, das darauf abzielt, mehrere Krankheitsmechanismen der spinalen und bulbären Muskelatrophie...
- ROSEN, LEADING INVESTOR COUNSEL, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - UNCYWHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) between December 29, 2025 and June 29, 2026, both dates inclusive (the “Class Period”), of the important November 2, 2026 lead plaintiff deadline.
- Spyre Therapeutics Announces Pricing of $350.0 Million Public Offering of Common StockSpyre Therapeutics, Inc. (“Spyre” or the “Company”) (Nasdaq: SYRE), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients, today announced the pricing of its previously announced underwritten public offering of 4,117,648 shares of its common stock at a price to the public of $85.00 per share. The gross proceeds to the Company from this offering are expected to be approximately $350.0 million, before deducting underwriting discounts and commissions and other offering expenses. In addition, the Company has granted the underwriters of the offering an option for a period of 30 days to purchase up to an additional approximately $52.5 million of shares of the Company's common stock offered in the public offering under the same terms and conditions. The offering is expected to close on or about October 7, 2026, subject to satisfaction of customary closing conditions.
- Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, on October 1, 2026, the Compensation Committee of the Board of Directors granted stock options to purchase an aggregate of 59,250 shares of Vor Bio’s common stock and restricted stock units (“RSUs”) representing the right to receive an aggregate of 12,550 shares of Vor Bio’s common stock to 9 newly hired employees. The foregoing stock options and RSUs were granted as material inducements to employment with Vor Bio in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted under the Vor Biopharma Inc. 2023 Inducement Plan (the “Inducement Plan”).
- Mozart TherapeuticsMozart Therapeutics Presents Clinical and Preclinical Data Supporting MTX-101 at the 62nd EASD Annual MeetingPresentations highlight Phase 1 clinical findings, proof-of-mechanism data, and translational evidence supporting the therapeutic potential of MTX-101 in adults and adolescents with Stage 3 type 1 diabetes SEATTLE, Oct. 5, 2026 -- Mozart Therapeutics, Inc. ("Mozart"), the...
- Vaxcyte Announces Commencement of Proposed Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior NotesVaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced that it has commenced underwritten public offerings of $500 million of its common stock and pre-funded warrants and $500 million aggregate principal amount of convertible senior notes due 2032 (the “notes”) in separate public offerings registered under the Securities Act of 1933, as amended. All shares of common stock, pre-funded warrants and notes to be sold in the offerings will be offered by Vaxcyte. Vaxcyte intends to grant the underwriters a 30-day option to purchase up to an additional $75 million of shares of its common stock, and expects to grant the underwriters a 30-day option to purchase up to an additional $75 million aggregate principal amount of notes solely to cover over-allotments. The completion of the common stock and pre-funded warrant offering will not be contingent on the completion of the note offering, and the completion of the note offering will not be contingent on the completion of the common stock and pre-funded warrant offering. The offerings are subject to market and other conditions, and there can be no assurance as to whether or when either offering may be completed, or as to the actual size or terms of either offering.
- Vir Biotechnology, Inc.Vir Biotechnology to Present Expanded Phase 2 SOLSTICE Results for Elebsiran and Tobevibart in Hepatitis Delta at AASLD’s The Liver Meeting® 2026SAN FRANCISCO, October 05, 2026--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will present data from the Phase 2 SOLSTICE trial evaluating the combination of elebsiran and tobevibart for chronic hepatitis delta at the upcoming American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2026 in Denver, CO, November 5-9, 2026.
- Verastem OncologyVerastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)BOSTON, October 05, 2026--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the grant of 380,500 restricted stock units (RSUs) to 24 new employees and stock options to purchase 50,000 shares of its common stock to one new employee. The awards were granted pursuant to the Nasdaq inducement grant exception as an inducement material to the employee’s acceptance of employment with Vera
- Neurogene Inc.Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NEW YORK, October 05, 2026--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 8,340 shares of the Company’s common stock to five new employees (the "Inducement Grants") on October 5, 2026 (the "Grant Date"). The Induce
- Italfarmaco S.p.A.Italfarmaco and VeriSIM Life Partner to Develop Novel HDAC-Targeting Therapeutics for Neuromuscular, Fibrotic, and Rare DiseasesSAN FRANCISCO & MILAN, October 05, 2026--Italfarmaco S.p.A., a global pharmaceutical company with established expertise in histone deacetylase (HDAC) biology and therapeutic development, and VeriSIM Life, an AI-enabled drug discovery and development company, today announced a strategic collaboration to discover and develop novel HDAC-targeted therapeutic assets for neuromuscular, fibrotic, and rare diseases.
- Genmab A/SGenmab and AbbVie Announce Epcoritamab in Combination with R-CHOP Demonstrates Statistically Significant Improvement in Progression-Free Survival in Patients with Newly Diagnosed Diffuse Large B-Cell LymphomaCompanies: AbbVieCOPENHAGEN, Denmark & NORTH CHICAGO, Ill., October 05, 2026--Genmab A/S (Nasdaq: GMAB) and AbbVie (NYSE: ABBV) announced today positive topline results from the Phase 3 EPCORE DLBCL-2 trial evaluating fixed treatment duration epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, in combination with standard of care rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisone (R-CHOP), compared to R-CHOP alone, in newly diagnosed patients with diff